特别提示： 证券代码：301230 证券简称：泓博医药 公告编号：2025-041 上海泓博智源医药股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 1、本次股东大会不存在新增、修改、否决议案的情形； 2、本次股东大会不存在变更前次股东大会决议的情形； 3、本次股东大会采取现场投票与网络投票相结合的方式进行。 一、会议召开情况 1、会议通知方式：公告方式 2、会议召开时间： （1）现场会议召开时间：2025 年 5 月 15 日（星期四）14:00 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 5 月 15 日上午 9:15~9:25，9:30~11:30 和下午 13:00~15:00；通过深圳证券交易所互联网 投票系统投票的具体时间为 2025 年 5 月 15 日 9:15～15:00 任意时间。 3、现场会议地点：上海浦东新区凯庆路 59 号 12 幢公司 101 会议室 4、会议召开方式：本次股东大会采取现场投票、网络投票相结合的方式。 5、会议召集人：公司董事会 参加 ...

Core Viewpoint - The report highlights the recovery of profitability for Hongbo Pharmaceutical, driven by stable revenue growth and the launch of the AI-enabled platform DiOrion, leading to an "Accumulate" rating for the company [1][8]. Financial Performance - In 2024, the company achieved revenue of 544 million yuan, a year-on-year increase of 11.18%, while the net profit attributable to shareholders was 17 million yuan, down 54.59% year-on-year [2]. - The first quarter of 2025 saw revenue of 169 million yuan, a year-on-year increase of 29.61%, with net profit attributable to shareholders rising to 12 million yuan, a significant increase of 226.47% [2]. Revenue and Profit Trends - Revenue showed stable growth, with quarterly figures for 2024 being 131 million, 135 million, 126 million, and 153 million yuan, respectively, and further growth in Q1 2025 to 169 million yuan [3]. - The company’s net profit margin improved, with the gross profit margin for Q1 2024 at 20.61% and increasing to 28.39% in Q1 2025 [3]. Business Segments - The drug discovery segment maintained steady growth, generating 317 million yuan in revenue, accounting for 58.14% of total revenue, with a year-on-year growth of 7.97% [4]. - The commercialization segment experienced rapid growth, achieving 165 million yuan in revenue, a year-on-year increase of 51.02% [4]. - The process research and development segment faced challenges, with revenue declining by 38.15% to 48 million yuan [4]. Client and Order Growth - The number of active clients in the CRO/CDMO segment grew significantly, reaching 399, a year-on-year increase of 99.50% [5]. - The company maintained a stable order backlog of 312 million yuan, with a slight year-on-year increase of 1.18% [5]. R&D Investment and AI Development - R&D investment reached 47 million yuan in 2024, a year-on-year increase of 26.58%, representing 8.68% of total revenue [6]. - The AI-enabled platform DiOrion, which integrates various drug discovery processes, has been successfully launched, enhancing the company's competitive edge [6]. Investment Outlook - The company is projected to achieve net profits of 404.2 million, 488.8 million, and 543.7 million yuan for 2025, 2026, and 2027, respectively, with corresponding EPS of 0.29, 0.35, and 0.39 yuan [7]. - The company’s comprehensive service platform and continuous R&D investment are expected to drive future growth, maintaining an "Accumulate" rating [8].

Investment Rating - The investment rating for the company is "Accumulate" [4][9] Core Views - The company has shown stable revenue growth, with a reported revenue of 544.47 million yuan in 2024, representing an 11.18% year-on-year increase. The first quarter of 2025 saw a revenue increase to 169 million yuan, a 29.61% year-on-year growth [4][5] - The company's profitability is on a recovery trend, with a significant increase in net profit for the first quarter of 2025, reaching 12 million yuan, a 226.47% year-on-year increase [4][5] - The drug discovery segment continues to grow steadily, while the commercialization segment has experienced rapid expansion, contributing significantly to revenue growth [5][6] - The company has successfully launched its AI-enabled platform DiOrion, which is expected to enhance drug discovery efficiency and innovation capabilities [7][8] Financial Performance Summary - In 2024, the company achieved a total revenue of 544.47 million yuan, with a projected revenue of 727.57 million yuan for 2025, indicating a growth rate of 33.63% [11] - The net profit for 2024 was 17.08 million yuan, with projections of 40.42 million yuan for 2025, reflecting a substantial growth rate of 136.61% [11] - The earnings per share (EPS) are expected to increase from 0.12 yuan in 2024 to 0.29 yuan in 2025 [11] Business Segments Overview - The drug discovery segment generated 317 million yuan in revenue in 2024, accounting for 58.14% of total revenue, with a year-on-year growth of 7.97% [5] - The commercialization segment achieved a revenue of 165 million yuan, growing by 51.02% year-on-year, indicating its role as a key driver of revenue growth [5] - The CRO/CDMO active client base grew to 399, a 99.50% increase year-on-year, showcasing effective client expansion efforts [6] R&D and Technological Advancements - The company invested 47 million yuan in R&D in 2024, a 26.58% increase from the previous year, with R&D expenses accounting for 8.68% of total revenue [7] - The DiOrion platform, which integrates generative AI capabilities, is expected to significantly enhance the company's drug discovery processes [7][8]

Investment Rating - The investment rating for the company is "Accumulate" [4][9] Core Views - The company has shown stable revenue growth with a reported revenue of 544.47 million yuan in 2024, representing an 11.18% year-on-year increase. The first quarter of 2025 saw a further increase in revenue to 169 million yuan, a 29.61% year-on-year growth [4][5] - The company's profitability is on a recovery trend, with the first quarter of 2025 showing a net profit of 12 million yuan, a significant increase of 226.47% year-on-year [4][5] - The drug discovery segment continues to grow steadily, while the commercialization segment has experienced rapid expansion, contributing significantly to revenue growth [5][6] - The company has successfully launched its AI-enabled platform DiOrion, which is expected to enhance drug discovery efficiency and innovation capabilities [7][8] Financial Summary - In 2024, the company achieved a total revenue of 544.47 million yuan, with a projected revenue of 727.57 million yuan for 2025, indicating a growth rate of 33.63% [11] - The net profit for 2024 was 17.08 million yuan, with projections of 40.42 million yuan for 2025, reflecting a growth rate of 136.61% [11] - The earnings per share (EPS) are expected to increase from 0.12 yuan in 2024 to 0.29 yuan in 2025 [11] Business Segments - The drug discovery segment generated 317 million yuan in revenue in 2024, accounting for 58.14% of total revenue, with a year-on-year growth of 7.97% [5] - The commercialization segment achieved a revenue of 165 million yuan, growing by 51.02% year-on-year, indicating its role as a key driver of revenue growth [5] - The company has expanded its active client base in the CRO/CDMO sector to 399 clients, a 99.50% increase year-on-year, demonstrating effective market expansion efforts [6]

出席本次年度业绩说明会的人员有：公司董事长兼总经理 PING CHEN 先生、董事 兼副总经理蒋胜力先生、独立董事尤启冬先生、财务总监李世成先生和董事会秘书李秋 丽女士。 为充分尊重投资者，提升交流的针对性，现就公司 2024 年度网上业绩说明会提前 向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2025 年 5 月 15 日 （星期四）15:00 前访问 http://ir.p5w.net/zj/，或扫描下方二维码，进入问题征集专题页 面进行提问。公司将在本次业绩说明会上对投资者普遍关注的问题进行回答。 证券代码：301230 证券简称：泓博医药 公告编号：2025-040 上海泓博智源医药股份有限公司 关于举行2024年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 上海泓博智源医药股份有限公司(以下简称"公司")于 2025 年 4 月 24 日披露了《2024 年年度报告》及《2024 年年度报告摘要》。为便于广大投资者进一步了解公司生产经营 等情况，公司定于 2025 年 5 月 16 日（星期五）15:00- ...

证券代码：301230 证券简称：泓博医药 公告编号：2025-039 特别提示： 截至本公告披露日，沈阳富邦投资有限责任公司（以下简称"沈阳富邦"）持有上海 泓博智源医药股份有限公司（以下简称"公司"或"本公司"）8,663,200 股，占公司扣除最 新披露的回购专户股份后总股本比例 6.30%。沈阳富邦计划在本公告发布之日起 15 个 交易日后的 3 个月内以集中竞价或大宗交易方式减持公司股份不超过 1,370,000 股，即 减持比例不超过公司扣除最新披露的回购专户股份后总股本的 1.00%。 上海泓博智源医药股份有限公司 关于持股5%以上股东减持计划的预披露公告 公司持股 5%以上股东沈阳富邦投资有限责任公司保证向本公司提供的信息内 容真实、准确、完整，没有虚假记载、误导性陈述或者重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 近日，本公司收到沈阳富邦出具的《关于股份减持计划的告知函》，现将有关 情况公告如下： 一、股东基本情况 1、股东名称：沈阳富邦投资有限责任公司 2、股东持股情况：截至本公告披露日，沈阳富邦持有公司股份 8,663,200 股，占公 司扣除最新披露 ...

（二）保荐代表人：王琦、李嵩 中信证券股份有限公司 关于上海泓博智源医药股份有限公司 2024 年持续督导培训情况的报告 深圳证券交易所： 中信证券股份有限公司（以下简称"中信证券""保荐人"）根据《深圳证 券交易所上市公司自律监管指引第 13 号——保荐业务》对上海泓博智源医药股 份有限公司（以下简称"泓博医药"、"公司"）进行了 2024 年度持续督导培 训，报告如下： 一、本次持续督导培训的基本情况 （一）保荐机构：中信证券股份有限公司 （三）培训时间：2025 年 4 月 24 日 （四）培训地点：泓博医药办公室现场及视频会议 （五）培训人员：王琦 （六）培训对象：公司董事、监事、高级管理人员以及部分关键岗位人员 （七）培训内容：本次培训通过案例与法规相结合的方式，阐述了上市公 司规范运作、募集资金管理、控股股东及实际控制人行为规范、内幕交易与泄 露内幕信息、担保与资金往来等；并通过解读近期证监会发布的规则，讲解了 资本市场近况。 二、上市公司的配合情况 保荐人本次持续督导培训的工作过程中，公司积极予以配合，保证了培训 工作的有序进行，达到了良好效果。 1 三、本次持续督导培训的结论 通过此次培训授课 ...

中信证券股份有限公司 关于上海泓博智源医药股份有限公司 2024年度跟踪报告 | 保荐人名称：中信证券股份有限公司 | 被保荐公司简称：泓博医药 | | --- | --- | | 保荐代表人姓名：王琦 | 联系电话：010-60833007 | | 保荐代表人姓名：李嵩 | 联系电话：010-60838329 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 无 | | 2．督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不 | | | 限于防止关联方占用公司资源的制度、募集资金 | 是 | | 管理制度、内控制度、内部审计制度、关联交易 | | | 制度） | | | （2）公司是否有效执行相关规章制度 | 是，根据《上海泓博智源医药股份有限公司内 部控制评价报告》、《上海泓博智源医药股份 | | | 有限公司内部控制审计报告》，发行人有效执 | | | 行了相关规章制度。 | | 3.募集资金 ...

关于上海泓博智源医药股份有限公司 2024 年度持续督导定期现场检查报告 | 保荐人名称：中信证券股份有限公司 被保荐公司简称：泓博医药 | | --- | | （以下简称"中信证券"或"保荐人"） | | 保荐代表人姓名：王琦 联系电话：010-60833007 | | 保荐代表人姓名：李嵩 联系电话：010-60838329 | | 现场检查人员姓名：王琦 | | 现场检查对应期间：2024 年 1 月 1 日-2024 年 12 月 31 日 | | 现场检查时间：2025 年 月 日 4 24 | | 一、现场检查事项 现场检查意见 | | （一）公司治理 是 否 不适用 | | 现场检查手段： | | 查阅了上市公司最新章程、三会议事规则及会议材料，取得上市公司董事、监事、 | | 高级管理人员名单及其变化情况，取得上市公司关联方清单，查阅关于公司控股 | | 股东、实际控制人、董事、监事、高级管理人员的信息披露文件及相关变更决策 | | 文件，查看上市公司生产经营场所，对上市公司董事长、董事会秘书、财务总监 | | 进行访谈。 | | 1.公司章程和公司治理制度是否完备、合规 是 | | 2.公司 ...

Policy Developments - The National Medical Products Administration (NMPA) released the "Quality Management Specifications for Online Sales of Medical Devices," effective from October 1, 2025, which emphasizes qualification review, information transparency, and risk prevention for online medical device sales [1] Drug and Device Approvals - Insilico Medicine's INS018_055 tablet is expected to receive breakthrough therapy designation for treating idiopathic pulmonary fibrosis [2] - Yuyuan Pharmaceutical's injectable Ganciclovir has passed the consistency evaluation for generic drugs, which will enhance the company's market share and competitiveness [3] - Warner Pharmaceuticals' Bismuth Potassium Citrate Granules have also passed the consistency evaluation for generic drugs, benefiting future market sales [4] - Changchun High-tech's subsidiary, Jinsai Pharmaceutical, received approval for clinical trials of Fuxin Qibai monoclonal antibody injection, aimed at treating endometriosis [5] Financial Reports - Yunnan Baiyao reported a Q1 2025 net profit of 1.935 billion yuan, a 13.67% increase year-on-year, with total revenue of 10.841 billion yuan, up 0.62% [6] - WuXi AppTec's Q1 2025 net profit surged by 89.06% to 3.672 billion yuan, driven by revenue growth and operational efficiency improvements [7][8] - Kefu Medical's 2024 annual report showed a net profit increase of 22.6% to 312 million yuan, with revenue of 2.983 billion yuan, up 4.53% [9] - Hongbo Pharmaceutical's Q1 2025 net profit increased by 226.47% to 11.974 million yuan, with revenue of 16.9 million yuan, up 29.61% [10] Capital Market Activities - Jiangsu Hengrui Medicine has received approval from the China Securities Regulatory Commission for its Hong Kong IPO, planning to issue up to 815.1 million shares [11] - Merck announced its acquisition of SpringWorks for approximately $3.9 billion in equity value [12] - China Merchants Bio intends to increase its stake in Renfu Pharmaceutical by 0.5%-1% within six months, reflecting confidence in the company's future [13] Industry Developments - Xiangyu Medical expects to obtain registration certificates for seven robotic products by 2025, focusing on rehabilitation and other medical applications [14] - Soundon Medical has formed a strategic partnership with MED-EL's BHM to advance global bone conduction hearing solutions [16] - Hanyu Pharmaceutical signed a comprehensive cooperation agreement with Huawei Cloud to focus on "AI Smart Drugs" in drug development [17] Public Sentiment Alerts - Innovative Medical announced that shareholder Shanghai Guanghuan Technology reduced its stake by 3.41 million shares, representing 0.8191% of the total circulating shares [18]